Incyte earns $19M milestone from Lilly

Wilmington, DE-based Incyte says that it earned a rich $19 million milestone from Eli Lilly after the pharma company launched the Phase IIb study of the rheumatoid arthritis drug INCB28050. Lilly inked a licensing pact covering Incyte's oral JAK1 and JAK2 inhibitor. The compound will now be referred to as LY3009104. Incyte release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.